Does the media refer more to BIOA or TNXP?

In the previous week, Tonix Pharmaceuticals had 4 more articles in the media than BioAge Labs. MarketBeat recorded 7 mentions for Tonix Pharmaceuticals and 3 mentions for BioAge Labs. Tonix Pharmaceuticals' average media sentiment score of 0.92 beat BioAge Labs' score of -0.54 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Tonix Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ALLO or TNXP?

In the previous week, Tonix Pharmaceuticals had 3 more articles in the media than Allogene Therapeutics. MarketBeat recorded 7 mentions for Tonix Pharmaceuticals and 4 mentions for Allogene Therapeutics. Tonix Pharmaceuticals' average media sentiment score of 0.92 beat Allogene Therapeutics' score of 0.89 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tonix Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, IVA or TNXP?

Tonix Pharmaceuticals has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $5.07M 162.64 -$400.67M N/A N/A Tonix Pharmaceuticals $13.11M 13.93 -$124.02M -$14.36 N/A

Does the media refer more to IVA or TNXP?

In the previous week, Tonix Pharmaceuticals had 5 more articles in the media than Inventiva. MarketBeat recorded 7 mentions for Tonix Pharmaceuticals and 2 mentions for Inventiva. Tonix Pharmaceuticals' average media sentiment score of 0.92 beat Inventiva's score of 0.66 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tonix Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tonix Pharmaceuticals (TNXP) Competitors

$11.46 -0.25 (-2.13%)

Closing price 04:00 PM Eastern

Extended Trading

$11.80 +0.34 (+2.97%)

As of 07:59 PM Eastern

Compare

TNXP vs. AURA, BIOA, RLMD, ALLO, and IVA

Should you buy Tonix Pharmaceuticals stock or one of its competitors? MarketBeat compares Tonix Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tonix Pharmaceuticals include Aura Biosciences (AURA), BioAge Labs (BIOA), Relmada Therapeutics (RLMD), Allogene Therapeutics (ALLO), and Inventiva (IVA). These companies are all part of the "pharmaceutical products" industry.

How does Tonix Pharmaceuticals compare to Aura Biosciences?

Tonix Pharmaceuticals (NASDAQ:TNXP) and Aura Biosciences (NASDAQ:AURA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

Aura Biosciences has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -839.52%. Tonix Pharmaceuticals' return on equity of -67.65% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%
Aura Biosciences	N/A	-78.12%	-64.08%

Tonix Pharmaceuticals currently has a consensus price target of $22.00, indicating a potential upside of 91.97%. Aura Biosciences has a consensus price target of $20.50, indicating a potential upside of 222.83%. Given Aura Biosciences' higher possible upside, analysts plainly believe Aura Biosciences is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are held by institutional investors. 2.0% of Tonix Pharmaceuticals shares are held by insiders. Comparatively, 6.3% of Aura Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Tonix Pharmaceuticals had 6 more articles in the media than Aura Biosciences. MarketBeat recorded 7 mentions for Tonix Pharmaceuticals and 1 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.87 beat Tonix Pharmaceuticals' score of 0.92 indicating that Aura Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Tonix Pharmaceuticals	Positive
Aura Biosciences	Very Positive

Aura Biosciences has lower revenue, but higher earnings than Tonix Pharmaceuticals. Aura Biosciences is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$13.11M	13.93	-$124.02M	-$14.36	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A

Tonix Pharmaceuticals has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market.

Summary

Aura Biosciences beats Tonix Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to BioAge Labs?

BioAge Labs (NASDAQ:BIOA) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

BioAge Labs has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market.

Tonix Pharmaceuticals has a net margin of -839.52% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-871.75%	-29.40%	-27.26%
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%

In the previous week, Tonix Pharmaceuticals had 4 more articles in the media than BioAge Labs. MarketBeat recorded 7 mentions for Tonix Pharmaceuticals and 3 mentions for BioAge Labs. Tonix Pharmaceuticals' average media sentiment score of 0.92 beat BioAge Labs' score of -0.54 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Tonix Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioAge Labs has higher earnings, but lower revenue than Tonix Pharmaceuticals. BioAge Labs is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$8.99M	78.12	-$80.61M	-$2.40	N/A
Tonix Pharmaceuticals	$13.11M	13.93	-$124.02M	-$14.36	N/A

BioAge Labs currently has a consensus target price of $43.50, suggesting a potential upside of 175.32%. Tonix Pharmaceuticals has a consensus target price of $22.00, suggesting a potential upside of 91.97%. Given BioAge Labs' stronger consensus rating and higher probable upside, equities analysts clearly believe BioAge Labs is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 20.8% of BioAge Labs shares are owned by insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

BioAge Labs beats Tonix Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to Relmada Therapeutics?

Tonix Pharmaceuticals (NASDAQ:TNXP) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 2.0% of Tonix Pharmaceuticals shares are held by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Tonix Pharmaceuticals presently has a consensus target price of $22.00, indicating a potential upside of 91.97%. Relmada Therapeutics has a consensus target price of $12.00, indicating a potential upside of 91.39%. Given Tonix Pharmaceuticals' higher possible upside, equities analysts clearly believe Tonix Pharmaceuticals is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Relmada Therapeutics has lower revenue, but higher earnings than Tonix Pharmaceuticals. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$13.11M	13.93	-$124.02M	-$14.36	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A

Tonix Pharmaceuticals has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

Relmada Therapeutics has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -839.52%. Tonix Pharmaceuticals' return on equity of -67.65% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%
Relmada Therapeutics	N/A	-71.22%	-64.46%

In the previous week, Tonix Pharmaceuticals had 6 more articles in the media than Relmada Therapeutics. MarketBeat recorded 7 mentions for Tonix Pharmaceuticals and 1 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 1.89 beat Tonix Pharmaceuticals' score of 0.92 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Tonix Pharmaceuticals	Positive
Relmada Therapeutics	Very Positive

Summary

Tonix Pharmaceuticals and Relmada Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Tonix Pharmaceuticals has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	31,408.65	-$190.89M	-$0.77	N/A
Tonix Pharmaceuticals	$13.11M	13.93	-$124.02M	-$14.36	N/A

Allogene Therapeutics has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -839.52%. Allogene Therapeutics' return on equity of -56.45% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%

In the previous week, Tonix Pharmaceuticals had 3 more articles in the media than Allogene Therapeutics. MarketBeat recorded 7 mentions for Tonix Pharmaceuticals and 4 mentions for Allogene Therapeutics. Tonix Pharmaceuticals' average media sentiment score of 0.92 beat Allogene Therapeutics' score of 0.89 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tonix Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Allogene Therapeutics presently has a consensus price target of $8.52, indicating a potential upside of 368.25%. Tonix Pharmaceuticals has a consensus price target of $22.00, indicating a potential upside of 91.97%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Allogene Therapeutics is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Allogene Therapeutics has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market.

Summary

Allogene Therapeutics beats Tonix Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to Inventiva?

Inventiva (NASDAQ:IVA) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

Inventiva has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market.

19.1% of Inventiva shares are held by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 32.0% of Inventiva shares are held by insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Inventiva presently has a consensus target price of $16.56, indicating a potential upside of 317.02%. Tonix Pharmaceuticals has a consensus target price of $22.00, indicating a potential upside of 91.97%. Given Inventiva's stronger consensus rating and higher probable upside, research analysts plainly believe Inventiva is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Tonix Pharmaceuticals had 5 more articles in the media than Inventiva. MarketBeat recorded 7 mentions for Tonix Pharmaceuticals and 2 mentions for Inventiva. Tonix Pharmaceuticals' average media sentiment score of 0.92 beat Inventiva's score of 0.66 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tonix Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inventiva has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -839.52%. Inventiva's return on equity of 0.00% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%

Tonix Pharmaceuticals has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	162.64	-$400.67M	N/A	N/A
Tonix Pharmaceuticals	$13.11M	13.93	-$124.02M	-$14.36	N/A

Summary

Inventiva beats Tonix Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get Tonix Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNXP vs. The Competition

Export

Metric	Tonix Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$186.67M	$2.95B	$6.68B	$11.95B
Dividend Yield	N/A	1.70%	2.67%	5.58%
P/E Ratio	-0.80	17.78	24.56	23.76
Price / Sales	13.93	705.38	566.69	129.97
Price / Cash	N/A	56.17	26.99	37.23
Price / Book	0.60	3.88	10.52	6.75
Net Income	-$124.02M	$75.85M	$3.56B	$337.35M
7 Day Performance	-2.22%	-1.46%	-1.11%	-2.54%
1 Month Performance	-18.67%	-5.33%	1.28%	1.42%
1 Year Performance	-70.77%	15.77%	21.20%	24.71%

Tonix Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNXP Tonix Pharmaceuticals	3.9564 of 5 stars	$11.46 -2.1%	$22.00 +92.0%	-71.2%	$186.67M	$13.11M	N/A	50	News Coverage
AURA Aura Biosciences	3.0566 of 5 stars	$7.45 -0.7%	$20.50 +175.4%	-0.3%	$771.81M	N/A	N/A	50	Positive News
BIOA BioAge Labs	2.4884 of 5 stars	$17.10 +0.3%	$43.50 +154.4%	N/A	$761.65M	$8.99M	N/A	N/A
RLMD Relmada Therapeutics	2.4227 of 5 stars	$7.18 -1.0%	$12.00 +67.1%	+585.1%	$753.22M	N/A	N/A	10	Positive News Gap Up
ALLO Allogene Therapeutics	2.7759 of 5 stars	$2.17 -3.8%	$8.52 +293.6%	+30.3%	$747.25M	$20K	N/A	310	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNXP) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tonix Pharmaceuticals (TNXP) Competitors

TNXP vs. AURA, BIOA, RLMD, ALLO, and IVA

How does Tonix Pharmaceuticals compare to Aura Biosciences?

Summary

How does Tonix Pharmaceuticals compare to BioAge Labs?

Summary

How does Tonix Pharmaceuticals compare to Relmada Therapeutics?

Summary

How does Tonix Pharmaceuticals compare to Allogene Therapeutics?

Summary

How does Tonix Pharmaceuticals compare to Inventiva?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP vs. The Competition

Tonix Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tonix Pharmaceuticals (TNXP) Competitors

TNXP vs. AURA, BIOA, RLMD, ALLO, and IVA

How does Tonix Pharmaceuticals compare to Aura Biosciences?

Is TNXP or AURA more profitable?

Do analysts prefer TNXP or AURA?

Do insiders & institutionals believe in TNXP or AURA?

Does the media favor TNXP or AURA?

Which has higher earnings & valuation, TNXP or AURA?

Which has more risk and volatility, TNXP or AURA?

Summary

How does Tonix Pharmaceuticals compare to BioAge Labs?

Which has more volatility and risk, BIOA or TNXP?

Is BIOA or TNXP more profitable?

Does the media refer more to BIOA or TNXP?

Which has better earnings and valuation, BIOA or TNXP?

Do analysts prefer BIOA or TNXP?

Do institutionals and insiders have more ownership in BIOA or TNXP?

Summary

How does Tonix Pharmaceuticals compare to Relmada Therapeutics?

Do institutionals and insiders believe in TNXP or RLMD?

Do analysts prefer TNXP or RLMD?

Which has higher valuation and earnings, TNXP or RLMD?

Which has more risk and volatility, TNXP or RLMD?

Is TNXP or RLMD more profitable?

Does the media favor TNXP or RLMD?

Summary

How does Tonix Pharmaceuticals compare to Allogene Therapeutics?

Do insiders and institutionals have more ownership in ALLO or TNXP?

Which has stronger valuation and earnings, ALLO or TNXP?

Is ALLO or TNXP more profitable?

Does the media refer more to ALLO or TNXP?

Do analysts recommend ALLO or TNXP?

Which has more volatility & risk, ALLO or TNXP?

Summary

How does Tonix Pharmaceuticals compare to Inventiva?

Which has more volatility & risk, IVA or TNXP?

Do insiders & institutionals have more ownership in IVA or TNXP?

Do analysts prefer IVA or TNXP?

Does the media refer more to IVA or TNXP?

Is IVA or TNXP more profitable?

Which has stronger valuation & earnings, IVA or TNXP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP vs. The Competition

Tonix Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools